Evanson Jeff's Form 4 filing
Outlook Therapeutics, Inc. (OTLK) · filed Jan 19, 2023
- Accession no.
- 0001209191-23-004118
- Filed
- Jan 19, 2023
- Trade date
- Jan 17-19, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $203.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Evanson JeffCIK 0001760511 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2023 | Common Stock | SSaleDisposed | −27,162 | $1.31 | −$35,582.22 | 1,149,968 | Direct | |
| Jan 18, 2023 | Common Stock | SSaleDisposed | −33,738 | $1.25 | −$42,172.5 | 1,116,230 | Direct | |
| Jan 19, 2023 | Common Stock | SSaleDisposed | −103,255 | $1.22 | −$125,971.1 | 1,012,975 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.